Norsworthy, Penny J. http://orcid.org/0000-0002-5572-8491
Thompson, Andrew G. B.
Mok, Tze H.
Guntoro, Fernando
Dabin, Luke C. http://orcid.org/0000-0001-6365-291X
Nihat, Akin
Paterson, Ross W. http://orcid.org/0000-0001-9372-3635
Schott, Jonathan M. http://orcid.org/0000-0003-2059-024X
Collinge, John
Mead, Simon http://orcid.org/0000-0002-4326-1468
Viré, Emmanuelle A.
Funding for this research was provided by:
Alzheimer's Research UK
DH | National Institute for Health Research
Alzheimer's Society
RCUK | Medical Research Council
Wolfson Foundation
RCUK | Engineering and Physical Sciences Research Council
Alzheimer's Research UK
MRC Dementias Platform UK Brain Research UK Weston Brain Institute European Union Horizon 2020
Article History
Received: 31 October 2019
Accepted: 9 July 2020
First Online: 7 August 2020
Competing interests
: Prof. Collinge is a director and shareholder of D-Gen Limited (London), an academic spinout company working in the field of prion disease diagnosis, decontamination and therapeutics. Prof. Schott has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen and Merck, GE; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen and GE; and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. All other authors declare no competing interests.